Skip to main content
SpringerLink
Log in

Bromocriptine and psychosis: A literature review

  • Articles
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

Bromocriptine is an ergot-derived dopamine agonist. Its current uses include the treatment of Parkinson's disease, postpartum ablaction, prolactionmas, acromegaly, and amenorrhea and galactorrhea secondary to neuroleptic use. It is often reported to produce psychiatric side effects such as confusion, hallucinations, and delusions. The literature is reviewed and supports a strong anecdotal relationship between bromocriptine use and psychosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sibley DR, Monsma FJ, Jr: Molecular biology of dopamine receptors. Trends in Pharmacological Sciences 13(Feb):61–69, 1992.

    Article  PubMed  Google Scholar 

  2. Wood DF, Johnston JM, Johnston DG: Dopamine, the dopamine receptor and putuitary tumors. Clinical Endocrinology 35:455–466, 1991.

    PubMed  Google Scholar 

  3. Davis KL, Kahn RS, Ko, G, et al: Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry 148(11):1474–1486, 1991.

    PubMed  Google Scholar 

  4. Parkes D: Bromocriptine. New England Journal of Medicine 301:873–878, 1979.

    PubMed  Google Scholar 

  5. Blackwell RE, Bradley EL, Kline LB, et al: Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study. Fertility and Sterility 39(6):744–748, 1983.

    PubMed  Google Scholar 

  6. Robbins RJ, Kern PA, Thompson TL: Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. American Journal of Medicine 76(5):921–923, 1984.

    Article  PubMed  Google Scholar 

  7. Brook NM, Cookson IB: Bromocriptine-induced mania? (Letter) British Medical Journal 1:790, 1978.

    Google Scholar 

  8. Vlissides DN, Gill D, Castelow J: Bromocriptine-induced mania? (Letter) British Medical Journal 1:510, 1978.

    Google Scholar 

  9. Lipper S: Psychosis in patient on bromocriptine and levodopa with carbidopa. Lancet 2(7985):571–572, 1976.

    Article  Google Scholar 

  10. Vogel HP, Schiffter R: Hypersexuality — a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatry 16:107–110, 1983.

    Google Scholar 

  11. Montastruc JL, Rascol O, Rascol A: A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. Journal of Neurology, Neurosurgery, and Psychiatry 52:773–775, 1989.

    Google Scholar 

  12. Ostergaard K, Dupont, E: Clozapine treatment of drug-induced psychotic symptoms of late stages of Parkinson's disease. Acta Neurologica Scandinavica 78:349–350, 1988.

    PubMed  Google Scholar 

  13. Scholz E, Dichgans J: Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. European Archives of Psychiatry and Neurological Sciences 235:60–64, 1985.

    Article  PubMed  Google Scholar 

  14. Serby M, Angrist B, Lieberman A: Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. American Journal of Psychiatry 135:1227–1229, 1978.

    PubMed  Google Scholar 

  15. Cummings, JL: Behavioral complications of drug treatment of Parkinson's disease. Journal of the American Geriatrics Society 39:708–716, 1991.

    PubMed  Google Scholar 

  16. Calne DB, Williams AC, Neophytides A, et al: Long-term treatment of Parkinsonism with bromocriptine. Lancet 1(8067):735–738, 1978.

    Article  PubMed  Google Scholar 

  17. Burton K, Larsen TA, Robinson RG, et al: Parkinson's disease: a comparison of mesulergine and bromocriptine. Neurology 35:1205–1208, 1985.

    PubMed  Google Scholar 

  18. Friedman JH, Max J, Swift, R: Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and l-dopa. Clinical Neuropharmacology 10(5):470–475, 1987.

    PubMed  Google Scholar 

  19. Iffy L, Lindenthal J, Szodi Z, et al: Puerperal psychosis following ablaction with bromocriptine. Medicine and Law 8(2):171–174, 1989.

    PubMed  Google Scholar 

  20. Canterbury RJ, Haskins B, Kahn N, et al: Postpartum psychosis induced by bromocriptine. Southern Medical Journal 80(11):1463–1464, 1987.

    PubMed  Google Scholar 

  21. Kemperman CJF, Zwanniken GJ: Psychiatric side effects of bromocriptine therapy for postpartum galactorrhoea. Journal of the Royal Society of Medicine 80:387–388, 1987.

    PubMed  Google Scholar 

  22. Lake CR, Reid A, Martin C, et al: Cyclothymic disorder and bromocriptine: predisposing factors for postpartum mania? Canadian Journal of Psychiatry 32:693–694, 1987.

    Google Scholar 

  23. Steinbeck K, Turtle JR: Treatment of acromegaly with bromocriptine. Australian and New Zealand Journal of Medicine 9:217–224, 1979.

    PubMed  Google Scholar 

  24. LeFeuvre CM, Isaacs AJ, Frank OS: Bromocriptine-induced psychosis in acromegaly. British Medical Journal 285:1315, 1982.

    Google Scholar 

  25. Vance ML, Evans WS, Thorner MO: Bromocriptine. Annals of Internal Medicine 100:78–91, 1984.

    PubMed  Google Scholar 

  26. Cabeza GA, Flores LF, Inigues IE, et al: Acute psychosis secondary to bromocriptine treatment in a patient with a prolactinoma. Revista de Investigacion Clinica 36(2):147–149, 1984.

    PubMed  Google Scholar 

  27. Einarson TR, Turchet, EN: Psychotic reaction to low-dose bromocriptine. Clinical Pharmacy 2(May–June):273–274, 1983.

    PubMed  Google Scholar 

  28. Turner TH, Cookson JC, Wass JAH, et al: Psychotic reactions during treatment of pituitary tumors with dopamine agonists. British Medical Journal 289:1101–1103, 1984.

    PubMed  Google Scholar 

  29. Shukla S, Turner WJ, Newman G: Bromocriptine-related psychosis and treatment. Biological Psychiatry 20:326–328, 1985.

    Article  PubMed  Google Scholar 

  30. Taneli B, Ozaskinli S, Kirli S, et al: Bromocriptine-induced schizophrenic syndrome. American Journal of Psychiatry 143(7):935, 1986.

    Google Scholar 

  31. Johnson JM: Treated mania exacerbated by bromocriptine. American Journal of Psychiatry 138:980–982, 1981.

    PubMed  Google Scholar 

  32. Pearson KC: Mental disorders from low dose bromocriptine (Letter). New England Journal of Medicine 305:173, 1978.

    Google Scholar 

  33. Procter AW, Littlewood R, Fry AH: Bromocriptine-induced psychosis in acromegaly. British Medical Journal 286:50, 1983.

    PubMed  Google Scholar 

  34. Frye PE, Pariser SF, Kim MH, et al: Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. Journal of Clinical Psychiatry 43(6):252–253, 1982.

    PubMed  Google Scholar 

  35. Dorevitch A, Aronzon R, Stark M: Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstetricia et Gynecologica Scandinavica 70:375–376, 1991.

    PubMed  Google Scholar 

  36. Turner WJ: Importance of treatment follow-up. Biological Psychiatry 28:551–554, 1990.

    Article  PubMed  Google Scholar 

  37. Einarson TR, Turchet EN: Follow-up on bromocriptine-induced psychosis. Clinical Pharmacy 2(Nov–Dec):512, 1983.

    Google Scholar 

  38. Beaumont PJV, Gelder MG, Friesen HG, et al: The effects of phenothiazines on endocrine function: I Patients with inappropriate lactation and amenorrhea. British Journal of Psychiatry 124:413–419, 1974.

    PubMed  Google Scholar 

  39. Beaumont P, Bruwer J, Pimstone B, et al: Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. British Journal of Psychiatry 126:285–288, 1975.

    PubMed  Google Scholar 

  40. Perovich RM, Lieberman JA, Fleischhacker WW, et al: The behavioral toxicity of bromocriptine in patients with psychiatric illness. Journal of Clinical Psychopharmacology 9(6):417–422, 1989.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tulane Medical Center, Department of Psychiatry and Neurology, Tulane University, 1430 Tulane Avenue, 70112-2699, New Orleans, Lousiana

    Alan Boyd D.O. (Resident)

Authors
  1. Alan Boyd D.O.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boyd, A. Bromocriptine and psychosis: A literature review. Psych Quart 66, 87–95 (1995). https://doi.org/10.1007/BF02238717

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02238717

Keywords

Search

Navigation